FINWIRES · TerminalLIVE
FINWIRES

Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

By

Alto Neuroscience (ANRO) said Tuesday it has initiated a Phase 2b trial of its candidate ALTO-207 in treatment-resistant depression.

The randomized, placebo-controlled study is designed to replicate positive results from the previous PAX-D study and streamline the drug's path toward regulatory registration, the company said. ALTO-207 is a novel, modified-release combination of pramipexole and ondansetron, according to the company.

The formulation aims to reduce nausea typically associated with pramipexole, allowing for higher dosing and faster titration, the company said. In an earlier Phase 2a trial, the drug demonstrated a statistically significant improvement in depression symptoms, measured by the Montgomery-Asberg Depression Rating Scale, the company said.

The trial will enroll about 178 adults in the US and UK who have failed multiple prior treatments, the company said. The primary goal is to measure changes in depression scores over an eight-week treatment period, and topline data are expected in H2 of 2027, the company said.

Price: $25.08, Change: $-2.26, Percent Change: -8.25%

Related Articles

Wire

IDP Education to Introduce Malaysia as Study Destination

IDP Education (ASX:IEL) expanded its range of study destinations by supporting students to study in Malaysia, according to a Tuesday statement.The company cited changing student preferences as a reason for the move, with growing demand for new destinations offering strong education quality, career outcomes, and affordable study options.The initial rollout will focus on a select number of markets as part of a phased pilot.IDP Education's shares declined 1% in recent trading on Tuesday.

ASX:IEL
Wire

Infratil Says Moody's Assigns CDC Data Centers 'Baa2' Rating, Stable Outlook

Infratil (NZE:IFT, ASX:IFT) said Moody's Ratings has assigned CDC Data Centers Australia its first public investment grade credit rating of "Baa2" with a stable outlook, according to Tuesday filings with the Australian and New Zealand bourses.The rating reflects CDC's strong financial position, stable long-term contracted revenues, and exceptionally long lease durations averaging 28.4 years, per the filing.The rating will enable CDC to improve access to capital markets, supporting further large-scale infrastructure development driven by rising demand from government, hyperscale cloud providers, and critical industries, the filing added.The company's Kiwi shares shed 1% in recent Tuesday trade.

ASX:IFTNZE:IFT
Wire

Spruce Biosciences Begins Public Offering of Stock, Prefunded Warrants; Shares Fall After Hours

Spruce Biosciences (SPRB) said late Monday it commenced an underwritten public offering of common shares or related prefunded warrants.The company expects to grant underwriters a 30-day option to buy up to 15% more stock at the public offering price, less underwriting discounts and commissions.The offering is subject to market and other conditions, Spruce said.Spruce shares fell 13% in after-hours trading.

$SPRB